BlossomHill Therapeutics closed $100 million in a Series B financing led by Colt Ventures to advance its pipeline of in-house discovery and development programs for multiple high-need cancers and autoimmune diseases.

BlossomHill Therapeutics announced the closing of a $100 million Series B financing round led by Colt Ventures, with participation from new and existing investors such as Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners LLC, Plaisance Capital Management LLC and H&D Asset Management, among others. The company plans to use the proceeds to advance its pipeline of multiple in-house discovery and development programs for multiple high-need cancers and autoimmune diseases into the clinic.